Lopinavir and ritonavir | 369372-47-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Lopinavir and ritonavir
• 英文别名: (2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide;1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
• CAS: 369372-47-4
• 化学式: C74H96N10O10S2
• 分子量: 1349.7
• InChiKey: OFFWOVJBSQMVPI-RMLGOCCBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.23
• 重原子数：
  96
• 可旋转键数：
  33
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  322
• 氢给体数：
  8
• 氢受体数：
  14

文献信息

• [EN] DERIVATIVES OF BETULIN<br/>[FR] DÉRIVÉS DE BÉTULINE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2013090664A1

  公开（公告）日：2013-06-20

  The present invention relates to compounds characterized by having a structure according to the following Formula I: (I), or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.

  本发明涉及具有以下式I结构的化合物，或其药用可接受的盐。本发明的化合物可用于治疗或预防HIV。
• 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT
  申请人：Cho Aesop

  公开号：US20110070194A1

  公开（公告）日：2011-03-24

  Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 2′ position of the nucleoside sugar is substituted with halogen and carbon substitutents. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections caused by both wild type and mutant strains of HCV.

  提供了吡咯并[1,2-f][1,2,4]三唑基，咪唑并[1,5-f][1,2,4]三唑基，咪唑并[1,2-f][1,2,4]三唑基，以及[1,2,4]三唑并[4,3-f][1,2,4]三唑基核苷，核苷酸磷酸酯和它们的前药，其中核苷糖的2'位置被卤素和碳取代基取代。提供的化合物、组合物和方法对于治疗黄病毒科病毒感染特别有效，尤其是治疗由HCV的野生型和突变株引起的丙型肝炎感染。
• DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET
  申请人：FUJI CHEMICAL INDUSTRY CO., LTD.

  公开号：EP2465539A1

  公开（公告）日：2012-06-20

  There has been a need for an orally rapidly disintegrating tablet which has a good texture and taste in the oral cavity, such a sufficient hardness as not giving any worry of being chipped or dusted during production or transportation and good disintegrating properties in the oral cavity and can sustain a sufficient hardness even under humid conditions after opening. Disclosed are a disintegrating particle composition which is prepared by dispersing, in the presence of water, mannitol, xylitol, an inorganic excipient, a disintegrating agent and carmellose and drying, and an orally rapidly disintegrating tablet which comprises said disintegrating particle composition, an active substance and a disintegrating agent. The disintegrating tablet has a good texture and taste, an appropriate hardness and good disintegrating properties and can sustain a sufficient hardness under humid conditions.

  人们需要一种口服快速崩解片剂，这种片剂在口腔中具有良好的质地和口感，有足够的硬度，不会担心在生产或运输过程中碎裂或沾上灰尘，在口腔中具有良好的崩解性能，即使在开封后潮湿的条件下也能保持足够的硬度。本发明公开了一种崩解颗粒组合物，其制备方法是在有水存在的情况下，将甘露醇、木糖醇、无机赋形剂、崩解剂和卡麦芽糖分散并干燥；还公开了一种口服快速崩解片剂，其包括所述崩解颗粒组合物、活性物质和崩解剂。该崩解片具有良好的质地和口感、适当的硬度和良好的崩解性能，并能在潮湿条件下保持足够的硬度。
• BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS
  申请人：Johann Wolfgang Goethe-Universität Frankfurt am Main

  公开号：EP3912679A1

  公开（公告）日：2021-11-24

  The invention is based on the fibrin-derived peptides as therapeutic compounds for the treatment of inflammatory complications of virally caused diseases, such as a diffuse inflammation of the endothelium, also known as systemic endotheliitis or vasculitis and related disorders. The use of certain fibrin derived peptides and analogues of these compounds resulted in a surprisingly effective patient recovery.

  本发明基于纤维蛋白衍生肽作为治疗化合物，用于治疗病毒引起的疾病的炎症并发症，如内皮细胞弥漫性炎症，也称为系统性内皮细胞炎或血管炎及相关疾病。使用某些纤维蛋白衍生肽和这些化合物的类似物后，病人的康复效果令人惊讶。
• [EN] COMBINED DRUG FOR TREATING CORONAVIRUS DISEASE 2019<br/>[FR] MÉDICAMENT COMBINÉ POUR LE TRAITEMENT D'UNE MALADIE LIÉE AU CORONAVIRUS 2019<br/>[ZH] 治疗新型冠状病毒肺炎的联合用药物
  申请人：SICHUAN UNIV WEST CHINA HOSPITAL

  公开号：WO2021259195A1

  公开（公告）日：2021-12-30

  一种联合用药物或试剂盒及其在制备用于治疗新型冠状病毒肺炎或中东呼吸综合征的药物中的用途，该联合用药物或试剂盒含有同时或分别给药的rSIFN-co与基线治疗药物，其中基线治疗药物是：1)洛匹那韦利托那韦；或2)阿比多尔；该联合用药物可有效改善中度至重度COVID-19患者的病情。